Literature DB >> 288077

Cell surface antigens of human melanoma identified by monoclonal antibody.

M Y Yeh, I Hellström, J P Brown, G A Warner, J A Hansen, K E Hellström.   

Abstract

Mouse NS-1 myeloma cells were fused with spleen cells from mice that had been immunized with cells from a human melanoma, M1804. Hybrid cells were grown in selective medium and tested for production of antibody to surface antigens of M1804 cells. Three hybrids that produced antibodies that bound to the melanoma cells but not to autologous skin fibroblasts were cloned. Antibodies produced by two of the clones were cytotoxic to M1804 cells in the presence of rabbit complement. Extensive specificity tests showed that the antibodies produced by the clones bound strongly only to M1804 cells; significant, although weaker, binding occurred with 2 of 11 allogeneic melanomas. Apart from weak binding of the antibody produced by one of the clones to a breast carcinoma, binding assays of five carcinomas, one sarcoma, and fibroblasts from 17 individuals were negative, as were cytotoxic tests of 10 lymphoblastoid cell lines and peripheral blood lymphocytes from 68 normal donors and 12 chronic lymphocytic leukemia patients. This suggests that we have identified one or more determinants of a melanoma-associated antigen(s), whose expression is limited to a small proportion of melanomas.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 288077      PMCID: PMC383723          DOI: 10.1073/pnas.76.6.2927

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  A microassay for antibody binding to tumor cell surface antigens using 125I-labelled protein a from Staphylococcus aureus.

Authors:  J P Brown; J M Klitzman; K E Hellström
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

2.  Demonstration of cell-mediated immunity to human neoplasms of various histological types.

Authors:  I Hellström; K E Hellström; H O Sjögren; G A Warner
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

3.  Some recent studies on cellular immunity to human melanomas.

Authors:  I Hellström; K E Hellström
Journal:  Fed Proc       Date:  1973-02

4.  Demonstration of antibodies against human malignant melanoma by immunofluorescence.

Authors:  D L Morton; R A Malmgren; E C Holmes; A S Ketcham
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

5.  A highly sensitive and reproducible microcytotoxicity assay for demonstrating cytotoxic antibodies to cell surface antigens.

Authors:  I Hellström; J P Brown; J M Klitzman; K E Hellström
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

6.  X-ray intensifying screens greatly enhance the detection by autoradiography of the radioactive isotopes 32P and 125I.

Authors:  R Swanstrom; P R Shank
Journal:  Anal Biochem       Date:  1978-05       Impact factor: 3.365

7.  Leukocyte adherence inhibition and specific immunoreactivity in malignant melanoma.

Authors:  W J Halliday; A E Maluish; J H Little; N C Davis
Journal:  Int J Cancer       Date:  1975-10-15       Impact factor: 7.396

8.  Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease.

Authors:  M G Lewis; R L Ikonopisov; R C Nairn; T M Phillips; G H Fairley; D C Bodenham; P Alexander
Journal:  Br Med J       Date:  1969-09-06

9.  Study of antibodies against human melanoma produced by somatic cell hybrids.

Authors:  H Koprowski; Z Steplewski; D Herlyn; M Herlyn
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

10.  Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.

Authors:  H Shiku; T Takahashi; H F Oettgen
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  39 in total

1.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.

Authors:  N Scholler; N Fu; Y Yang; Z Ye; G E Goodman; K E Hellström; I Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 2.  Human tumor-associated antigens identified by monoclonal antibodies.

Authors:  K E Hellström; I Hellström; J P Brown
Journal:  Springer Semin Immunopathol       Date:  1982

Review 3.  Hybridomas: a new dimension in biological analyses.

Authors:  R H Kennett
Journal:  In Vitro       Date:  1981-12

4.  Logistics of tumor immunology.

Authors:  H Kirchner
Journal:  Klin Wochenschr       Date:  1982-01-04

5.  Monoclonal antibody against ependymoma-derived cell line.

Authors:  Y Mihara; Y Matsukado; S Goto; Y Ushio; S Tokumitsu; K Takahashi
Journal:  J Neurooncol       Date:  1992-01       Impact factor: 4.130

6.  Myeloma with multiple rearranged immunoglobulin kappa genes: only one kappa gene codes for kappa chains.

Authors:  U Storb; B Arp; R Wilson
Journal:  Nucleic Acids Res       Date:  1980-10-24       Impact factor: 16.971

7.  Detection of phenotypic differences on human malignant melanoma lines and their variant sublines with monoclonal antibodies.

Authors:  J Brüggen; C Sorg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.

Authors:  J P Brown; R G Woodbury; C E Hart; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

9.  Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen.

Authors:  G M Stuhlmiller; T L Darrow; D M Haupt; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.

Authors:  Shilin Yang; Yi Yang; John Raycraft; Hongtao Zhang; Sandra Kanan; Yajun Guo; Ze'ev Ronai; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.